Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Phase I study designed to test the hypothesis that overencapsulated celecoxib 200 mg qd is
bioequivalent to commercial celecoxib 200 mg qd. Approximately 90 healthy volunteers will be
randomized to yield approximately 80 completers. The study is an open label, randomized,
2-way crossover with single dosing followed by a 7-day washout period between treatment arms